Vertex ends gene editing deal with Verve amid R&D shift
FierceBiotech - 27-Feb-2025Verve regains full rights to its liver disease program as it moves forward independently
Nick Paul Taylor
Details last updated 13-Mar-2019
Articles written by Nick Paul Taylor
ALS drug trials face setbacks but offer glimmers of hope
FierceBiotech - 07-Jan-2025Fosigotifator and DNL343 miss key goals, sparking calls for deeper analysis and longer studies
Khondrion's sonlicromanol faces setback in phase 2 trial, but holds onto hope
FierceBiotech - 22-Nov-2024Long-term follow-up data and post-hoc analyses fuel optimism for treating mitochondrial diseases
Regenxbio-AbbVie gene therapy reduces eye injections for AMD patients
FierceBiotech - 17-Jan-2024Patients’ vision and retinal health remained stable after six months
J&J extends $30m deal with Nanobiotix for global co-development of radioenhancer
FierceBiotech - 10-Jul-2023NBTXR3 to enhance the effect of immunotherapies; plans for phase 3 trial in head and neck cancer
Korify Capital plans to invest $100m in longevity and mental health space
FierceBiotech - 22-Dec-2021Aiming to invest in 15-20 biotech firms, including Cambrian Biopharma, to target drivers of ageing
FDA puts clinical hold on Allogenic CAR T therapy due to safety concerns
FierceBiotech - 08-Oct-2021Chromosome abnormality reported in a clinical trial raises doubts on patient safety
Bristol Myers and insitro harness AI to tackle ALS and dementia
FierceBiotech - 28-Oct-2020A $2B partnership seeks to transform drug discovery with AI and stem cell models
$95M raised by Taysha for clinical trials of four new gene therapies
FierceBiotech - 05-Aug-2020Company has gathered support from investors to quickly lead therapies to clinic then market
Adicet merges with resTorbio for CAR T-cell therapy pipeline funding
FierceBiotech - 30-Apr-2020The deal moves company forward to initiating phase 1 trials in non-Hodgkin lymphoma next year
New $100m fund wants to give us 30 years extra healthspan
FierceBiotech - 05-Feb-2019Aiming for a market of billions of people, not just the richest
